


**Ce document liste les publications des travaux
des équipes de recherche du Cancéropôle Grand Ouest,
sorties d'avril à juin 2021, classées par réseaux du CGO.**

**Pour accéder plus rapidement aux publications des réseaux qui vous intéressent,
vous pouvez cliquer directement sur les logos ci-dessous :**



Et pour les publications inter-réseaux :



Réseau « Vectorisation, Imagerie, Radiothérapies »

[Synthesis of Poly\(Malic Acid\) Derivatives End-Functionalized with Peptides and Preparation of Biocompatible Nanoparticles to Target Hepatoma Cells](#)

Clarisse Brossard, Manuel Vlach, Elise Vène, Catherine Ribault, Vincent Dorcet, Nicolas Noiret, Pascal Loyer, Nicolas Lepareur, Sandrine Cammas-Marion

Nanomaterials (Basel) . 2021 Apr 9;11(4):958. **CGO remercié (AOE CGO 2017)**

[18F-FET PET/CT in Early Subventricular Zone Recurrence of Adult Glioblastoma.](#)

Dissaux G, Dissaux B, Bourhis D, Schick U, Querellou S.

Clin Nucl Med. 2021 Apr 1.

[Can alternative PET reconstruction schemes improve the prognostic value of radiomic features in non-small cell lung cancer?](#)

Tankyevych O, Tixier F, Antonorsi N, Filali Razzouki A, Mondon R, Pinto-Leite T, Visvikis D, Hatt M, Cheze Le Rest C.

Methods. 2021 Apr;188:73-83.

[Prediction of recurrence after surgery in colorectal cancer patients using radiomics from diagnostic contrast-enhanced computed tomography: a two-center study.](#)

Badic B, Da-Ano R, Poirot K, Jaouen V, Magnin B, Gagnière J, Pezet D, Hatt M, Visvikis D.

Eur Radiol. 2021 Jun 25.

[Statistical harmonization can improve the development of a multicenter CT-based radiomic model predictive of nonresponse to induction chemotherapy in laryngeal cancers.](#)

Masson I, Da-Ano R, Lucia F, Doré M, Castelli J, Goislard de Monsabert C, Ramée JF, Sellami S, Visvikis D, Hatt M, Schick U.

Med Phys. 2021 May 19.

[Simultaneous mapping of vasculature, hypoxia and proliferation using DSC-MRI, 18F-FMISO PET, and 18F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma.](#)

Collet S, Guillamo JS, Berro DH, Chakhoyan A, Constans JM, Lechapt-Zalcman E, Derlon JM, Hatt M, Visvikis D, Guillouet S, Perrio C, Bernaudin M, Valable S.

J Nucl Med. 2021 May 20;jnumed.120.249524.

[Comparison and Fusion of Machine Learning Algorithms for Prospective Validation of PET/CT Radiomic Features Prognostic Value in Stage II-III Non-Small Cell Lung Cancer.](#)

Sepeshri S, Tankyevych O, Upadhaya T, Visvikis D, Hatt M, Cheze Le Rest C.

Diagnostics (Basel). 2021 Apr 9;11(4):675.

[Accuracy of noncontact surface imaging for tidal volume and respiratory rate measurements in the ICU.](#)

L'Her E, Nazir S, Pateau V, Visvikis D.

J Clin Monit Comput. 2021 Apr 22:1-9.

[Radiomics Analysis of 3D Dose Distributions to Predict Toxicity of Radiotherapy for Cervical Cancer.](#)

Lucia F, Bourbonne V, Visvikis D, Miranda O, Gujral DM, Gouders D, Dissaux G, Pradier O, Tixier F, Jaouen V, Bert J, Hatt M, Schick U.

J Pers Med. 2021 May 11;11(5):398.

[Integration of functional imaging in brachytherapy.](#)

Lucia F, Miranda O, Bourbonne V, Martin E, Pradier O, Schick U.
Cancer Radiother. 2021 Jun 22;S1278-3218(21)00099-8.

[Clinical perspectives for the use of total body PET/CT.](#)

Abgral R, Bourhis D, Salaun PY.
Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1712-1718.

[Ferrocifen Loaded Lipid Nanocapsules: A Promising Anticancer Medication against Multidrug Resistant Tumors.](#)

Idlas P, Lepeltier E, Jaouen G, Passirani C.
Cancers (Basel). 2021 May 11;13(10):2291.

[A Monte Carlo Determination of Dose and Range Uncertainties for Preclinical Studies with a Proton Beam.](#)

Bongrand A, Koumeir C, Villoing D, Guertin A, Haddad F, Métivier V, Poirier F, Potiron V, Servagent N, Supiot S, Delpon G, Chiavassa S.
Cancers (Basel). 2021 Apr 15;13(8):1889.

[Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".](#)

Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF.
Pharmaceutics. 2021 Jun 18;13(6):906.

[Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.](#)

Mikolajczak R, Huclier-Markai S, Alliot C, Haddad F, Szikra D, Forgacs V, Garnuszek P.
EJNMMI Radiopharm Chem. 2021 May 25;6(1):19.

[Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trials.](#)

Jamet B, Morvan L, Nanni C, Michaud AV, Bailly C, Chauvie S, Moreau P, Touzeau C, Zamagni E, Bodet-Milin C, Kraeber-Bodéré F, Mateus D, Carlier T.
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1005-1015.

[Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.](#)

Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve H, Gressin R, Bouhabdallah K, Haioun C, Damaj G, Fornecker L, Bouhabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodéré F, Bodet-Milin C, Berriolo-Riedinger A, Brière J, Jais JP, Molina TJ, Itti E, Casasnovas RO.
Blood. 2021 Apr 29;137(17):2307-2320.

[Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.](#)

Blanc-Durand P, Jégou S, Kanoun S, Berriolo-Riedinger A, Bodet-Milin C, Kraeber-Bodéré F, Carlier T, Le Gouill S, Casasnovas RO, Meignan M, Itti E.
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1362-1370.

[Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review of in vitro and Preclinical Imaging Studies.](#)

Dagallier C, Avry F, Touchefeu Y, Buron F, Routier S, Chérel M, Arlicot N.
Front Med (Lausanne). 2021 Jun 8;8:675209.

[SIRP \$\alpha\$ -specific monoclonal antibody enables antibody-dependent phagocytosis of neuroblastoma cells.](#)

Bahri M, Kailayangiri S, Vermeulen S, Galopin N, Rossig C, Paris F, Fougeray S, Birklé S.
Cancer Immunol Immunother. 2021 May 22.

[Interconversion between Möbius chiroptical states sustained by hexaphyrin dynamic coordination.](#)

Boitrel B, Le Gac S.
Chem Commun (Camb). 2021 Apr 14;57(29):3559-3562.

[Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations.](#)

Ebert MA, Gulliford S, Acosta O, de Crevoisier R, McNutt T, Heemsbergen WD, Witte M, Palma G, Rancati T, Fiorino C.
Phys Med Biol. 2021 Jun 17;66(12).

[Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: Biological strategy, design and quality control.](#)

Nguyen PV, Allard-Vannier E, Chourpa I, Hervé-Aubert K.
Int J Pharm. 2021 Jun 10;605:120795.

[Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells.](#)

Corvaglia V, Ait Mohamed Amar I, Garambois V, Letast S, Garcin A, Gongora C, Del Rio M, Denevault-Sabourin C, Joubert N, Huc I, Pourquier P.
Pharmaceuticals (Basel). 2021 Jun 28;14(7):624.

[A Highly Efficient One-for-All Nanodroplet for Ultrasound Imaging-Guided and Cavitation-Enhanced Photothermal Therapy.](#)

Qin D, Zhang L, Zhu H, Chen J, Wu D, Bouakaz A, Wan M, Feng Y.
Int J Nanomedicine. 2021 Apr 30;16:3105-3119.

Réseau « Cancers des Tissus Hormono-dépendants »

[Stratifying patients with intermediate-risk prostate cancer: Validation of a new model based on MRI parameters and targeted biopsy and comparison with NCCN and AUA subclassifications.](#)

Diamand R, Ploussard G, Roumiguié M, Malavaud B, Oderda M, Gontero P, Fourcade A, Fournier G, Benamran D, Iselin C, Fiard G, Descotes JL, Peltier A, Simone G, Roche JB, Roumeguère T, Albisinni S.
Urol Oncol. 2021 May;39(5):296.e1-296.e9.

[Impact of EPclin on adjuvant therapeutic decision making and comparison of EPclin to the PREDICT tool.](#)

Bourien H, Quillien V, Godey F, Perrin C, Le Du F, Guillermet S, Blanchot J, Lavoué V, Campillo-Gimenez B, Brunot A, Crouzet L, De la Motte Rouge T, Diéras V, Lefeuvre-Plesse C.
Int J Biol Markers. 2021 May 22:17246008211012424

[TRIM21, a New Component of the TRAIL-Induced Endogenous Necrosome Complex.](#)

Simoes Eugénio M, Faurez F, Kara-Ali GH, Lagarrigue M, Uhart P, Bonnet MC, Gallais I, Com E, Pineau C, Samson M, Le Seyec J, Dimanche-Boitrel MT.
Front Mol Biosci. 2021 Apr 15;8:645134.



[Nuclear translocation of MRTFA in MCF7 breast cancer cells shifts ER \$\alpha\$ nuclear/genomic to extra-nuclear/non genomic actions.](#)

Jehanno C, Percevault F, Boujrad N, Le Goff P, Fontaine C, Arnal JF, Primig M, Pakdel F, Michel D, Métivier R, Flouriot G.

Mol Cell Endocrinol. 2021 Jun 15;530:111282.

[Exercise training as a modulator of epigenetic events in prostate tumors.](#)

Dufresne S, Guéritat J, Wong CP, Isanejad A, Ho E, Serna E, Gomez-Cabrera MC, Rebillard A.

Prostate Cancer Prostatic Dis. 2021 May 18.

[Prostate cancer detection by targeted prostate biopsy using the 3D Navigo system: a prospective study.](#)

Magnier A, Nedelcu C, Chelly S, Rousselet-Chapeau MC, Azzouzi AR, Lebdaï S.

Abdom Radiol (NY). 2021 Apr 15

[\[High-intensity focused ultrasound for locally prostate cancer: An Afro-Caribbean single-center study\].](#)

Deleuze C, Blanchet P, Gourtaud G, Sénéchal C, Roux V, Brureau L, Eyraud R.

Prog Urol. 2021 Jun 18:S1166-7087(21)00030-0.

[Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.](#)

Leon P, Cancel-Tassin G, Bourdon V, Buecher B, Oudard S, Brureau L, Jouffe L, Blanchet P, Stoppa-Lyonnet D, Coulet F, Sobol H, Cussenot O.

Prostate. 2021 May;81(6):318-325.

[Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.](#)

Goetz MP, Okera M, Wildiers H, Campone M, Grischke EM, Manso L, André VAM, Chouaki N, San Antonio B, Toi M, Sledge GW Jr.

Breast Cancer Res Treat. 2021 Apr;186(2):417-428.

[Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database.](#)

Carasu M, Carton M, Darlix A, Pasquier D, Leheurteur M, Debled M, Mouret-Reynier MA, Goncalves A, Dalenc F, Verret B, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lefeuvre-Plesse C, Petit T, Uwer L, Jouannaud C, Larrouquere L, Chevrot M, Courtinard C, Cabel L.

ESMO Open. 2021 Jun;6(3):100150.

[Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.](#)

Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De la Motte Rouge T, Laborde L, Laurent C, Chamorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreuve C, Bachelot T, Robain M, Lerebours F.

Breast. 2021 Apr;56:18-25.

[Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.](#)

Roumiguié M, Paoletti X, Neuzillet Y, Mathieu R, Vincendeau S, Kleinclauss F, Mejean A, Guy L, Timsit MO, Lebret T.

Future Oncol. 2021 May;17(14):1811-1823.

[Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohort☆.](#)

Houvenaeghel G, de Nonneville A, Cohen M, Chopin N, Coutant C, Reyat F, Mazouni C, Gimbergues P, Azuar AS, Chauvet MP, Classe JM, Daraï E, Martinez A, Rouzier R, de Lara CT, Lambaudie E, Barrou J, Goncalves A. ESMO Open. 2021 Jun;6(3):100151.

[Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis.](#)

Samiei S, Simons JM, Engelen SME, Beets-Tan RGH, Classe JM, Smidt ML; EUBREAST Group. JAMA Surg. 2021 Jun 1;156(6):e210891

[ACOSOG Z-0011 criteria impact on axillary surgery for early breast cancer in clinical practice: Evaluation in a retrospective cohort of 1900 patients.](#)

Dolivet E, Loaec C, Johnson A, Renaudeau C, Boiffard F, Dravet F, Brillaud Meflah V, Classe JM. Eur J Obstet Gynecol Reprod Biol. 2021 Jun;261:41-45.



Réseau « Immunothérapies »

[Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?](#)

Camuset M, Huault A, Grain A, Clémenceau B, Riolland F, Thomas C, Chevallier P, Béné MC, Eveillard M. Hematol Oncol. 2021 Apr;39(2):270-272.

[Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma.](#)

Lejeune M, Duray E, Peipp M, Clémenceau B, Baron F, Beguin Y, Caers J. Cancers (Basel). 2021 Jun 20;13(12):3072.

[Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response.](#)

Makanga DR, Jullien M, David G, Legrand N, Willem C, Dubreuil L, Walencik A, Touzeau C, Gastinne T, Tessoulin B, Le Gouill S, Mahé B, Gagne K, Chevallier P, Clémenceau B, Retière C. Oncoimmunology. 2021 Jun 14;10(1):1936392.

[Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study.](#)

Monestier S, Dalle S, Mortier L, Dutriaux C, Dalac-Rat S, Meyer N, Leccia MT, Mansard S, Montaudié H, Saiag P, Combemale P, Guillot B, Skowron F, Duval Modeste AB, Bénéton N, Hainaut E, Robert C, Arnault JP, Le Corre Y, Jouary T, Ameur N, Varey E, Khammari A, Dréno B; RIC-Mel network. Int J Cancer. 2021 Jun 1;148(11):2789-2798.

[Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients.](#)

Dréno B, Khammari A, Fortun A, Vignard V, Saiagh S, Beauvais T, Jouand N, Bercegay S, Simon S, Lang F, Labarrière N. Cancer Immunol Immunother. 2021 Jun 12.

[Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels.](#)

Scard C, Nguyen JM, Varey E, Moustaghfir I, Khammari A, Dreno B.
Eur J Dermatol. 2021 Apr 1;31(2):205-212.

[Complete spontaneous regression of primary Merkel cell carcinoma with tumoural infiltration: a systematic review.](#)

Ah-Thiane L, Samimi M, Kervarrec T, Khammari A, Dréno B.
Eur J Dermatol. 2021 Jun 1. doi: 10.1684/ejd.2021.4065.

[Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development.](#)

Sun S, Frontini F, Qi W, Hariharan A, Ronner M, Wipplinger M, Blanquart C, Rehrauer H, Fonteneau JF, Felley-Bosco E.
Cancer Lett. 2021 Jun 1;507:26-38.

[A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients.](#)

Chevallier P, Saiagh S, Dehame V, Guillaume T, Peterlin P, Bercegeay S, Le Bris Y, Bossard C, Gauvrit I, Dreno B, Juge-Morineau N, Béné MC, Gregoire M.
Hum Vaccin Immunother. 2021 Jun 21:1-4.

[Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor \(AMHRII\) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogramming and T Cell Activation.](#)

Prat M, Salon M, Allain T, Dubreuil O, Noël G, Preisser L, Jean B, Cassard L, Lemée F, Tabah-Fish I, Pipy B, Jeannin P, Prost JF, Barret JM, Coste A.
Cancers (Basel). 2021 Apr 13;13(8):1845.

[Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: A retrospective study.](#)

Jaouen F, Kervarrec T, Caille A, Le Corre Y, Dreno B, Esteve E, Wierzbicka-Hainaut E, Maillard H, Dinulescu M, Blom A, Saïag P, Samimi M.
J Am Acad Dermatol. 2021 Apr;84(4):921-929.

[Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma.](#)

Becquart O, Oriano B, Dalle S, Mortier L, Leccia MT, Dutriaux C, Dalac S, Montaudié H, De Quatrebarbes J, Brunet-Possenti F, Saiag P, Lesimple T, Beylot-Barry M, Aubin F, Stoebner PE, Arnault JP, Dreno B, Porcher R, Lebbe C, Guillot B.
Cancers (Basel). 2021 Jun 18;13(12):3042.

[5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAF V600 Mutation-Positive Advanced Melanoma: Extended Follow-Up of the coBRIM Study.](#)

Ascierto PA, Dreno B, Larkin J, Ribas A, Liskay G, Maio M, Mandal M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Atkinson V, Dutriaux C, Garbe C, Hsu JJ, Jones S, Li H, McKenna E, Voulgari A, McArthur GA.
Clin Cancer Res. 2021 Jun 22:clincanres.0809.2021.

[Late-onset adverse events under anti-PD1 therapy in melanoma patients: an observational study from MELBASE, a nationwide prospective cohort.](#)

Carlet C, Dalle S, Leccia MT, Mortier L, Dalac-Rat S, Dutriaux C, Legoupil D, Montaudié H, Dereure O, De Quatrebarbes J, Granel-Brocard F, Le-Bouar M, Charles J, Brunet-Possenti F, Dreno B, Lefevre W, Allayous C, Lebbe C, Nardin C.

J Am Acad Dermatol. 2021 Jun 18:S0190-9622(21)01991-5.

[Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study.](#)

Herbreteau G, Vallée A, Knol AC, Théoleyre S, Quéreux G, Varey E, Khammari A, Dréno B, Denis MG.

Cancers (Basel). 2021 Apr 11;13(8):1826.

[Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study.](#)

Passot C, Sberro-Soussan R, Bertrand D, Caillard S, Schvartz B, Domenger C, Contin-Bordes C, Paintaud G, Halimi JM, Ternant D, Gatault P.

Br J Clin Pharmacol. 2021 May;87(5):2236-2246.

[Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.](#)

Petitcollin A, Azzopardi N, Pierga JY, Ternant D, Navarro-Teulon I, Desvignes C, Mouret-Reynier MA, Coudert B, Paintaud G.

Eur J Clin Pharmacol. 2021 Jul 10.

[Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal Administration.](#)

Le Tilly O, Azzopardi N, Bonneau C, Desvignes C, Oberkamp F, Ezzalfani M, Ternant D, Turbiez I, Gutierrez M, Paintaud G.

Clin Pharmacol Ther. 2021 Jul;110(1):210-219.

[Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients.](#)

Thibault G, Paintaud G, Sung HC, Lajoie L, Louis E, The Getaid, Desvignes C, Watier H, Gouilleux-Gruart V, Ternant D.

Int J Mol Sci. 2021 Jun 3;22(11):6051.

[Panitumumab and cetuximab affect differently miRNA expression in colorectal cancer cells.](#)

Chautard R, Corset L, Ibrahim S, Desvignes C, Paintaud G, Baroukh N, Guéguinou M, Lecomte T, Raoul W.

Biomark Med. 2021 Jun;15(10):685-696.

[Serum Antibodies Against the Oncogenic Merkel Cell Polyomavirus Detected by an Innovative Immunological Assay With Mimotopes in Healthy Subjects.](#)

Mazziotta C, Lanzillotti C, Torreggiani E, Oton-Gonzalez L, laquinta MR, Mazzoni E, Gaboriaud P, Touzé A, Silvagni E, Govoni M, Martini F, Tognon M, Rotondo JC.

Front Immunol. 2021 Jun 8;12:676627.

[Efficacy and tolerance of BRAF and MEK inhibitors on metastatic melanoma carrying the orphan pV600 K601 delinsE mutation of the BRAF gene.](#)

Barbé J, Garnier M, Tallet A, Collin C, Leducq S, Routier É, Machet L, Samimi M.
nt J Dermatol. 2021 Jul;60(7):e283-e284.



Réseau « Niches et Epigénétique des Tumeurs »

[DNA hypomethylating agents increase activation and cytolytic activity of CD8⁺ T cells.](#)

Loo Yau H, Bell E, Ettayebi I, de Almeida FC, Boukhaled GM, Shen SY, Allard D, Morancho B, Marhon SA, Ishak CA, Gonzaga IM, da Silva Medina T, Singhanian R, Chakravarthy A, Chen R, Mehdipour P, Pommey S, Klein C, Amarante-Mendes GP, Roulois D, Arribas J, Stagg J, Brooks DG, De Carvalho DD.
Mol Cell. 2021 Apr 1;81(7):1469-1483.e8.

[Tumor Vessels Fuel the Fire in Glioblastoma.](#)

Rosińska S, Gavard J
Int J Mol Sci. 2021 Jun 17;22(12):6514.

[ICG-001, an Inhibitor of the \$\beta\$ -Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells.](#)

Danieau G, Morice S, Renault S, Brion R, Biteau K, Amiaud J, Cadé M, Heymann D, Lézot F, Verrecchia F, Rédini F, Brounais-Le Royer B.
Pharmaceuticals (Basel). 2021 May 1;14(5):421.

[Letter to the editor with regard to the article entitled "Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes".](#)

Eveillard M, Béné MC, Hérault O.
Cytometry B Clin Cytom. 2021 May 5.

[Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response.](#)

El Hafny-Rahbi B, Brodaczewska K, Collet G, Majewska A, Klimkiewicz K, Delalande A, Grillon C, Kieda C.
J Cell Mol Med. 2021 Apr;25(7):3284-3299.

[Mass Cytometry Identifies Expansion of T-bet⁺ B Cells and CD206⁺ Monocytes in Early Multiple Sclerosis.](#)

Couloume L, Ferrant J, Le Gallou S, Mandon M, Jean R, Bescher N, Zephir H, Edan G, Thouvenot E, Ruet A, Debouverie M, Tarte K, Amé P, Roussel M, Michel L.
Front Immunol. 2021 May 4;12:653577.

[B cell/stromal cell crosstalk in health, disease, and treatment: Follicular lymphoma as a paradigm.](#)

Lamaison C, Tarte K.
Immunol Rev. 2021 May 31.

[Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape.](#)

Mourcin F, Verdière L, Roulois D, Amin R, Lamaison C, Sibut V, Thamphy B, Pangault C, Monvoisin C, Huet S, Seffals M, Baulande S, Mechta-Grigoriou F, Legoix P, Rossille D, Guirriec M, Léonard S, Cartron G, Salles G, Fest T, Tarte K.
Immunity. 2021 Jun 17:S1074-7613(21)00225-9.

[Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.](#)

Ménard C, Rossille D, Dulong J, Nguyen TT, Papa I, Latour M, Bescher N, Bezier I, Chouteau M, Fest T, Houot R, Morschhauser F, Tarte K.
Blood Adv. 2021 Apr 27;5(8):2063-2074.

[Interplay between Metabolism Reprogramming and Epithelial-to-Mesenchymal Transition in Cancer Stem Cells.](#)

Daniel Y, Lelou E, Aninat C, Corlu A, Cabillic F.
Cancers (Basel). 2021 Apr 20;13(8):1973.

[Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial-Mesenchymal State in Cancer Cells.](#)

Huna A, Nawrocki-Raby B, Padilla-Benavides T, Gavard J, Coscoy S, Bernard D, Boissan M.
Int J Mol Sci. 2021 Apr 2;22(7):3718.

[Apoptotic mesenchymal stromal cells support osteoclastogenesis while inhibiting multinucleated giant cells formation in vitro.](#)

Humbert P, Brennan MÁ, De Lima J, Brion R, Adrait A, Charrier C, Brulin B, Trichet V, Couté Y, Blanchard F, Layrolle P.
Sci Rep. 2021 Jun 9;11(1):12144.

Réseau « Molécules Marines, Métabolisme et Cancer »

[Synthetic alkyl-ether-lipid promotes TRPV2 channel trafficking through PI3K/Akt-girdin axis in cancer cells and increases mammary tumour volume.](#)

Guéguinou M, Felix R, Marionneau-Lambot S, Oullier T, Penna A, Kouba S, Gambade A, Fourbon Y, Ternant D, Arnoult C, Simon G, Bouchet AM, Chantôme A, Harnois T, Haelters JP, Jaffrès PA, Weber G, Bognoux P, Carreaux F, Mignen O, Vandier C, Potier-Cartereau M.
Cell Calcium. 2021 Jun 12;97:102435. **CGO remercié. 5 équipes du réseau**

[Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein.](#)

Smadja J, Quéméner A, Maillasson M, Sicard B, Leray A, Arzel L, Lebreton J, Mortier E, Dubreuil D, Mathé-Allainmat M.
Bioorg Med Chem. 2021 Jun 1;39:116161.

[TIPS-Diazoacetone Aldol Addition: Mechanistic Aspects and Contribution to the Synthesis.](#)

Gavelle S, Abid I, Biletskyi B, Henrion S, Hémon-Ribaud A, Lhoste J, Martel A, Dujardin G, Gaulon-Nourry C. J Org Chem. 2021 Apr 2;86(7):4917-4931.

[Design, Synthesis, In Silico and In Vitro Studies for New Nitric Oxide-Releasing Indomethacin Derivatives with 1,3,4-oxadiazole-2-thiol Scaffold.](#)

Sava A, Buron F, Routier S, Panainte A, Bibire N, Constantin SM, Lupaşcu FG, Focşa AV, Profire L.
Int J Mol Sci. 2021 Jun 30;22(13):7079. 5



[Risk factors for recurrence of borderline ovarian tumors in France: A multicenter retrospective study by the FRANCOGYN group.](#)

Sangnier E, Ouldamer L, Bendifallah S, Huchon C, Collinet P, Bricou A, Mimoun C, Lecointre L, Graesslin O, Raimond E.

J Gynecol Obstet Hum Reprod. 2021 Apr;50(4):101961.

[Stable Isotope Abundance and Fractionation in Human Diseases.](#)

Tea I, De Luca A, Schiphorst AM, Grand M, Barillé-Nion S, Mirallié E, Drui D, Krempf M, Hankard R, Tcherkez G.

Metabolites. 2021 Jun 9;11(6):370.

[Lymphovascular space invasion as a prognostic factor of epithelial ovarian cancer: a multicenter study by the FRANCOGYN group.](#)

Lorenzini J, Cirier J, Body G, Touboul C, Dabi Y, Collinet P, Coutant C, Akladios C, Lavoué V, Bolze PA, Huchon C, Bricou A, Canlorbe G, Ballester M, Carcopino X, Mimoun C, Bendifallah S, Ouldamer L; FRANCOGYN Research Group.

Arch Gynecol Obstet. 2021 Jun 29.

[Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.](#)

Zhang T, Sun B, Zhong C, Xu K, Wang Z, Hofman P, Nagano T, Legras A, Breadner D, Ricciuti B, Divisi D, Schmid RA, Peng RW, Yang H, Yao F.

Transl Lung Cancer Res. 2021 Apr;10(4):1857-1872.

[Panitumumab and cetuximab affect differently miRNA expression in colorectal cancer cells.](#)

Chautard R, Corset L, Ibrahim S, Desvignes C, Paintaud G, Baroukh N, Guéguinou M, Lecomte T, Raoul W.

Biomark Med. 2021 Jun;15(10):685-696.



Réseau « Sciences Humaines et Sociales »

[Return to work of breast cancer survivors: toward an integrative and transactional conceptual model.](#)

Porro B, Durand MJ, Petit A, Bertin M, Roquelaure Y.

J Cancer Surviv. 2021 May 5:1-14.

[Bullying, supervisor support, relaxation, and personal and work outcomes: Testing a moderated mediation model.](#)

Gillet N, Fernet C, Colombat P, Cheyroux P, Fouquereau E.

J Nurs Manag. 2021 Apr 12.

[An explanatory model of authentic leadership, flourishing and work-family balance of nurses in French hospitals.](#)

Chevalier S, Coillot H, Colombat P, Bosselut G, Guilbert L, Fouquereau E.

Leadersh Health Serv (Bradf Engl). 2021 May 27



Publications inter-réseaux

Réseaux « Vectorisation, Imagerie, Radiothérapies » & « Cancers des Tissus Hormono-dépendants »

[Prostate Bed Delineation Guidelines for Postoperative Radiation Therapy: On Behalf Of The Francophone Group of Urological Radiation Therapy.](#)

Robin S, Jolicoeur M, Palumbo S, Zilli T, Crehange G, De Hertogh O, Derashodian T, Sargos P, Salembier C, Supiot S, Udrescu C, Chapet O.

Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1243-1253.

[Brachytherapy boost \(BT-boost\) or stereotactic body radiation therapy boost \(SBRT-boost\) for high-risk prostate cancer \(HR-PCa\).](#)

Peyraga G, Lizee T, Khalifa J, Blais E, Mauriange-Turpin G, Supiot S, Khili S, Tremolieres P, Graff-Cailleaud P.

Cancer Radiother. 2021 Jun;25(4):400-409.

[Late Gastrointestinal Tolerance After Prostate Radiotherapy: Is the Anal Canal the Culprit? A Narrative Critical Review.](#)

Sargos P, Faye MD, Bacci M, Supiot S, Latorzeff I, Azria D, Niazi TM, Vuong T, Vendrely V, de Crevoisier R.

Front Oncol. 2021 Jun 16;11:666962.

Réseau « Vectorisation, Imagerie, Radiothérapies » & « Molécules Marines, Métabolisme et Cancer »

[Development of PET Radioligands Targeting COX-2 for Colorectal Cancer Staging, a Review of *in vitro* and Preclinical Imaging Studies.](#)

Dagallier C, Avry F, Touchefeu Y, Buron F, Routier S, Chérel M, Arlicot N.

Front Med (Lausanne). 2021 Jun 8;8:675209. Review.

Réseaux « Molécules Marines, Métabolisme et Cancer » & « Cancers des Tissus Hormono-dépendants »

[Total long-chain polyunsaturated n-3 fatty acids level is an independent predictive factor of breast cancer multifocality in women with positive hormone-receptors tumors.](#)

Ouldamer L, Goupille C, Vildé A, Arbion F, Guimaraes C, Jourdan ML, Bougnoux P, Body G, Chevalier S.

Surg Oncol. 2021 Apr 29;38:101597. **CGO remercié.**

[Zeb1 and SK3 Channel Are Up-Regulated in Castration-Resistant Prostate Cancer and Promote Neuroendocrine Differentiation.](#)

Bery F, Cancel M, Guéguinou M, Potier-Cartreau M, Vandier C, Chantôme A, Guibon R, Bruyère F, Fromont G, Mahéo K.

Cancers (Basel). 2021 Jun 12;13(12):2947.

[Identification of a Positive Association between Mammary Adipose Cholesterol Content and Indicators of Breast Cancer Aggressiveness in a French Population.](#)

Goupille C, Ouldamer L, Pinault M, Guimaraes C, Arbion F, Jourdan ML, Frank PG.

J Nutr. 2021 May 11;151(5):1119-1127.

Réseau « Vectorisation, Imagerie, Radiothérapies » & « Immunothérapies »

[Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.](#)

Marotte L, Capita M, Deleine C, Beauvais T, Cadiou G, Perrin J, Chérel M, Scotet E, Guilloux Y, Bruchertseifer F, Morgenstern A, Jarry A, Gaschet J, Labarriere N.

Oncoimmunology. 2021 Jun 27;10(1):1940676.



Réseau « Vectorisation, Imagerie, Radiothérapies » & « Niches et Epigénétique des Tumeurs »

[pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization.](#)

Pautu V, Lepeltier E, Mellinger A, Riou J, Debuigne A, Jérôme C, Clere N, Passirani C

Cancers (Basel). 2021 Apr 22;13(9):2028.

